Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer
- PMID: 14522255
- DOI: 10.1016/s1535-6108(03)00215-0
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer
Abstract
The murine Pten prostate cancer model described in this study recapitulates the disease progression seen in humans: initiation of prostate cancer with prostatic intraepithelial neoplasia (PIN), followed by progression to invasive adenocarcinoma, and subsequent metastasis with defined kinetics. Furthermore, while Pten null prostate cancers regress after androgen ablation, they are capable of proliferating in the absence of androgen. Global assessment of molecular changes caused by homozygous Pten deletion identified key genes known to be relevant to human prostate cancer, including those "signature" genes associated with human cancer metastasis. This murine prostate cancer model provides a unique tool for both exploring the molecular mechanism underlying prostate cancer and for development of new targeted therapies.
Similar articles
-
Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.Cancer Res. 2005 Jul 1;65(13):5730-9. doi: 10.1158/0008-5472.CAN-04-4519. Cancer Res. 2005. PMID: 15994948
-
Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2884-9. doi: 10.1073/pnas.042688999. Epub 2002 Feb 19. Proc Natl Acad Sci U S A. 2002. PMID: 11854455 Free PMC article.
-
The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.PLoS One. 2008;3(12):e3940. doi: 10.1371/journal.pone.0003940. Epub 2008 Dec 15. PLoS One. 2008. PMID: 19081794 Free PMC article.
-
Akt in prostate cancer: possible role in androgen-independence.Curr Drug Metab. 2003 Dec;4(6):487-96. doi: 10.2174/1389200033489226. Curr Drug Metab. 2003. PMID: 14683476 Review.
-
Apoptosis in prostate cancer: progressive and therapeutic implications (Review).Int J Mol Med. 2004 Jul;14(1):23-34. Int J Mol Med. 2004. PMID: 15202013 Review.
Cited by
-
Metastatic hormone-naïve prostate cancer: a distinct biological entity.Trends Cancer. 2024 Sep;10(9):825-841. doi: 10.1016/j.trecan.2024.06.005. Epub 2024 Jul 23. Trends Cancer. 2024. PMID: 39048488 Free PMC article. Review.
-
ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression.Nat Commun. 2022 Nov 26;13(1):7281. doi: 10.1038/s41467-022-34871-9. Nat Commun. 2022. PMID: 36435834 Free PMC article.
-
Lipids and prostate cancer.Prostaglandins Other Lipid Mediat. 2012 May;98(1-2):1-10. doi: 10.1016/j.prostaglandins.2012.03.003. Epub 2012 Apr 5. Prostaglandins Other Lipid Mediat. 2012. PMID: 22503963 Free PMC article. Review.
-
Regulating Androgen Receptor Function in Prostate Cancer: Exploring the Diversity of Post-Translational Modifications.Cells. 2024 Jan 19;13(2):191. doi: 10.3390/cells13020191. Cells. 2024. PMID: 38275816 Free PMC article. Review.
-
Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis.Carcinogenesis. 2012 Jul;33(7):1391-8. doi: 10.1093/carcin/bgs153. Epub 2012 Apr 25. Carcinogenesis. 2012. PMID: 22535887 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials